NASDAQ:AVBP ArriVent BioPharma Q2 2025 Earnings Results & Report $16.09 -0.37 (-2.25%) Closing price 04:00 PM EasternExtended Trading$16.50 +0.41 (+2.57%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ArriVent BioPharma missed analyst earnings expectations in its Q2 2025 results, released August 11, 2025. The company reported EPS of -$0.90 versus the -$0.70 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 11, 2025TimeBefore Market OpensConference Call8:00 AM ET ArriVent BioPharma EPS ResultsActual EPS-$0.90Consensus EPS -$0.70Beat/MissMissed by -$0.20One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersArriVent BioPharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsArriVent BioPharma's Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ArriVent BioPharma Q2 2025 Earnings FAQ Did ArriVent BioPharma beat earnings estimates for Q2 2025? ArriVent BioPharma (NASDAQ:AVBP) reported earnings of -$0.90 per share for Q2 2025, missing the consensus estimate of -$0.70. The report was announced on Monday, August 11, 2025. When is ArriVent BioPharma's next earnings date? ArriVent BioPharma's next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for ArriVent BioPharma on the company's earnings history page. ArriVent BioPharma Earnings HeadlinesArriVent BioPharma Doses First Patient in Phase 1 Trial of ARR-002 for Ovarian, Endometrial Cancer35 minutes ago | finance.yahoo.comArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & KorsinskyOctober 13 at 3:10 PM | prnewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 13 at 1:00 AM | Porter & Company (Ad)ArriVent BioPharma Doses First Patient in Phase 1 U.S. Trial of ARR-002 for Ovarian and Endometrial CancerOctober 12 at 4:31 PM | quiverquant.comQArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002October 12 at 4:01 PM | globenewswire.comAVBP Stock Gets Increased EPS Estimate from HC WainwrightOctober 12 at 1:13 AM | americanbankingnews.comSee More ArriVent BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ArriVent BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ArriVent BioPharma and other key companies, straight to your email. Email Address About ArriVent BioPharmaArriVent BioPharma (NASDAQ:AVBP) is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets. ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations. Furmonertinib has been approved in China for certain EGFR-mutated non-small cell lung cancer indications and is being evaluated by ArriVent in additional patient populations and geographies. The company obtained rights to develop and commercialize furmonertinib outside Greater China through a partnership with Allist Pharmaceuticals. ArriVent is headquartered in the United States and is advancing its programs through clinical trials intended to support potential regulatory submissions in the United States and other international markets. Its pipeline and development strategy are centered on targeted oncology therapies for patients whose tumors have actionable genetic alterations.View ArriVent BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
